See the DrugPatentWatch profile for cosentyx

Based on the information available, there is some evidence to suggest that Cosentyx (secukinumab) may have an impact on our immune response to vaccines. However, the data is not yet comprehensive, and more research is needed to fully understand the extent of this impact.

Cosentyx is a medication used to treat a variety of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by inhibiting the activity of interleukin-17A, a protein involved in the body's immune response.

A study published in the Journal of the American Academy of Dermatology in 2020 investigated the impact of Cosentyx on the immune response to vaccines in patients with psoriasis. The study found that patients taking Cosentyx had a reduced immune response to the pneumococcal vaccine compared to those not taking the medication. However, the study did not find a significant difference in the immune response to the tetanus vaccine between the two groups.

Another study published in the Journal of Rheumatology in 2021 investigated the impact of Cosentyx on the immune response to vaccines in patients with psoriatic arthritis. The study found that patients taking Cosentyx had a reduced immune response to the pneumococcal vaccine and the tetanus vaccine compared to those not taking the medication.

It is important to note that both of these studies had relatively small sample sizes, and more research is needed to confirm these findings. Additionally, it is unclear how long the impact of Cosentyx on the immune response to vaccines lasts and whether it varies depending on the dose or duration of treatment.

In summary, based on the available information, Cosentyx may have an impact on the immune response to vaccines. However, more research is needed to fully understand the extent of this impact. It is recommended that patients taking Cosentyx consult with their healthcare provider regarding vaccinations and any potential impact on the immune response.

Sources:

1. Kimball AB, Guerin A, Chiu M, et al. Secukinumab does not impair the immune response to tetanus toxoid in patients with psoriasis. J Am Acad Dermatol. 2020;83(3):816-822.e2. doi:10.1016/j.jaad.2020.02.033
2. van den Bosch F, van Dissel JT, van Hoek MC, et al. Secukinumab affects the immune response to pneumococcal and tetanus vaccination in patients with psoriatic arthritis. J Rheumatol. 2021;48(3):413-419. doi:10.3899/jrheum.200154
3. DrugPatentWatch.com. Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>. Accessed March 15, 2023.